Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
Sell
34
CNMD Quote, Financials, Valuation and Earnings
Last price:
$56.79
Seasonality move
:
0.43%
Day range:
$56.42 - $57.56
52-week range:
$46.00 - $78.58
Dividend yield:
1.41%
P/E ratio:
14.93x
P/S ratio:
1.34x
P/B ratio:
1.80x
Volume:
284.1K
Avg. volume:
438.3K
1-year change:
-25.01%
Market cap:
$1.8B
Revenue:
$1.3B
EPS (TTM):
$3.80
Analysts' Opinion
-
Consensus RatingConmed has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $65.67, Conmed has an estimated upside of 15.71% from its current price of $56.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $57.00 representing 100% downside risk from its current price of $56.75.
Fair Value
-
According to the consensus of 4 analysts, Conmed has 15.71% upside to fair value with a price target of $65.67 per share.
CNMD vs. S&P 500
-
Over the past 5 trading days, Conmed has underperformed the S&P 500 by -0.63% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Conmed does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Conmed has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Conmed reported revenues of $321.3M.
Earnings Growth
-
Conmed earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Conmed reported earnings per share of $0.19.
Enterprise value:
2.6B
EV / Invested capital:
--
Price / LTM sales:
1.34x
EV / EBIT:
14.41x
EV / Revenue:
1.99x
PEG ratio (5yr expected):
0.33x
EV / Free cash flow:
15.88x
Price / Operating cash flow:
10.74x
Enterprise value / EBITDA:
10.31x
Gross Profit (TTM):
$738.8M
Return On Assets:
5.16%
Net Income Margin (TTM):
9.02%
Return On Equity:
12.88%
Return On Invested Capital:
6.38%
Operating Margin:
4.97%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.3B | $1.3B | $312.3M | $321.3M | |
| Gross Profit | $590.6M | $692.9M | $738.8M | $172M | $177.8M | |
| Operating Income | $60.3M | $142.9M | $181.3M | $35M | $16M | |
| EBITDA | $18.9M | $214.9M | $253.3M | $53.1M | $34.2M | |
| Diluted EPS | -$3.25 | $2.61 | $3.80 | $0.63 | $0.19 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $424.4M | $488.3M | $610.1M | $635.7M | $639M | |
| Total Assets | $1.7B | $1.8B | $2.3B | $2.3B | $2.3B | |
| Current Liabilities | $182.2M | $187.6M | $320.7M | $291.4M | $283.1M | |
| Total Liabilities | $1B | $996.2M | $1.6B | $1.5B | $1.3B | |
| Total Equity | $725.6M | $789.5M | $752.5M | $854.7M | $977.6M | |
| Total Debt | $745.4M | $715.8M | $1.1B | $990.8M | $892.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $29.2M | $158.3M | $179.4M | $29.1M | $41.5M | |
| Cash From Investing | -$250.1M | -$17.8M | -$14M | -$2M | -$2.9M | |
| Cash From Financing | $222.9M | -$132.8M | -$162.4M | -$17M | -$28.4M | |
| Free Cash Flow | $6.8M | $141.5M | $164.6M | $27.1M | $37.8M | |
CNMD
Sector
Market Cap
$1.8B
$33.4M
Price % of 52-Week High
72.22%
45.25%
Dividend Yield
1.41%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-25.01%
-40%
Beta (5-Year)
1.186
0.653
Dividend yield:
1.41%
Annualized payout:
$0.80
Payout ratio:
20.78%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$57.25
200-day SMA
Sell
Level
$65.55
Bollinger Bands (100)
Sell
Level
54.07 - 67.03
Chaikin Money Flow
Buy
Level
727.3K
20-day SMA
Sell
Level
$57.95
Relative Strength Index (RSI14)
Sell
Level
49.69
ADX Line
Buy
Level
18.39
Williams %R
Neutral
Level
-68.6212
50-day SMA
Buy
Level
$55.82
MACD (12, 26)
Buy
Level
1.83
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-1.9M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3262)
Sell
CA Score
(Annual)
Level (-0.3551)
Buy
Beneish M-Score
(Annual)
Level (-2.547)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.094)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
Stock Forecast FAQ
In the current month, CNMD has received 0 Buy ratings 4 Hold ratings, and 0 Sell ratings. The CNMD average analyst price target in the past 3 months is $65.67.
-
Where Will Conmed Stock Be In 1 Year?
According to analysts, the consensus estimate is that Conmed share price will rise to $65.67 per share over the next 12 months.
-
What Do Analysts Say About Conmed?
Analysts are divided on their view about Conmed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Conmed is a Sell and believe this share price will drop from its current level to $57.00.
-
What Is Conmed's Price Target?
The price target for Conmed over the next 1-year time period is forecast to be $65.67 according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is CNMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Conmed is a Hold. 4 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CNMD?
You can purchase shares of Conmed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Conmed shares.
-
What Is The Conmed Share Price Today?
Conmed was last trading at $56.79 per share. This represents the most recent stock quote for Conmed. Yesterday, Conmed closed at $56.75 per share.
-
How To Buy Conmed Stock Online?
In order to purchase Conmed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
